ליקסומיה 10 מק"ג - Lyxumia 10 mcg
ש××× ×× !
×ת×ר××: 21.2.2021 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ת×ר××: 21.2.2021 ×תק××× ××××¢× ×× ×©×××ק ×תר××¤× ××פסק ×צ××ת×ת.
×ק×ר: ××©×¨× ××ר×××ת - ××××¢×ת ×¢× ×פסקת ש×××ק תר×פ×ת
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | ||||||
|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | A10BJ Glucagon-like peptide-1 (GLP-1) analogues | |||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| |||||
| צ×רת ××ª× | תת-×¢××¨× - S.C | |||||
| צ×רת ××× ×× | ת×××¡× ×××רק×, SOLUTION FOR INJECTION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | |||||
| ×ת×××× | For the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
| |||||
× ×ª×× × ×¡× [ ×צ×× ]
| ||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
××× ×¢××× ×ר××¤× | |||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| [ ××קס×××× 10 ×ק"×] ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | SANOFI - AVENTIS DEUTSCHLAND GMBH, GERMANY |
| ×©× ××¢× ×ר×ש×× | SANOFI - AVENTIS ISRAEL LTD |
| ר×ש××× | ת×ר×× ××ש×: 02/2013. ר×ש××× ×ת×ר××: 06/2014 |
| ת×ר×× ×¢×××× ××ר×× | 21.2.2021 |
××××¢ × ×סף ×ר×פ×××
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש ××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ××רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
×××ר××
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש ××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ××רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
- ×× ××× ××קס××××
- Lixisenatide ×××××× ×¢× ×¡××רת ס×× 2 ×תס××× ×ª ×××××ת ××× (acute coronary syndrome)
- ××קס××× ×××× - Lixisenatide
- פ×ק×ס ××קס××× ××
- ××¢×××ת Lyxumia ××××× ××××ת××× - ת×צ××ת ××¢×§× ×©× 24 ש×××¢×ת ×××¨× 1437 ×××× ×¡××רת ס×× 2